56
Registered trials
27
Recruiting
18
Completed trials
34
Sponsors
19
Countries
Phase III:
9
Phase II/III:
3
Phase II:
30
Phase I/II:
5
Phase IV:
1
Phase I:
1
Phase I (FiH):
7
Oversight events:
1 serious breach
7 temporary halts
1 corrective measure
across 3 trials
View oversight register →
Indications tested
Non-small cell lung cancer
15
Non-small cell lung cancer stage III
4
Non-small cell lung cancer metastatic
3
Malignant melanoma
3
Ovarian cancer recurrent
2
Fallopian tube cancer
2
Non-small cell lung cancer stage IV
2
Peritoneal cancer index
2
Non-small cell lung cancer stage IIIA
1
PD-L1 positive cancer
1
Squamous cell carcinoma
1
Bladder cancer
1
Sponsors using this IMP
Regeneron Pharmaceuticals Inc.
17
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
2
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
2
Institut Gustave Roussy
2
Intergroupe Francophone De Cancerologie Thoracique
2
Maia Biotechnology Inc.
2
Unicancer
2
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
1
BioNTech SE
1
CatalYm GmbH
1
Centre Hospitalier Universitaire D'Angers
1
ETOP IBCSG Partners Foundation
1
All trials — page 3
56 totalShowing 49–56 of 56 trials